MicroPort CardioFlow Medtech Corporation announced a discloseable and connected transaction to acquire the remaining 49% equity interest in MP CardioAdvent. This acquisition, detailed in an agreement dated May 30, 2025, involves purchasing approximately 35.27% from MicroPort Sinica and 13.73% from Shanghai Zuoqing. Upon completion, MP CardioFlow will fully own MP CardioAdvent, enhancing its focus on innovative solutions for structural heart diseases. The transaction, subject to regulatory approvals, is significant under the listing rules due to its size.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.